Facial Basal Cell Carcinoma Treated with Topical 5% Imiquimod Cream with Dermoscopic Evaluation

Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Surgical excision is considered to be the primary therapeutic modality wherever possible. For inoperable cases, 5% imiquimod seems to be a good alternative. We present two cases of nodular pigmented BCCs on the face in elderly women successfully treated with 5% imiquimod cream application resulting in complete clinical clearance of lesion as well as on histology and dermatoscopy. There was no recurrence of the lesion on 2 years follow-up for the first and 1.5 years for the second patient.

[1]  A. Marzuka,et al.  Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management , 2015, The Yale journal of biology and medicine.

[2]  J. Carucci,et al.  Advances in the management of basal cell carcinoma , 2015, F1000prime reports.

[3]  Chen Li-hua,et al.  Successful Treatment of Giant Basal Cell Carcinoma with Topical Imiquimod 5% Cream with Long Term Follow-up , 2014, Indian journal of dermatology.

[4]  P. Carli,et al.  In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod‐treated basal cell carcinoma , 2009, International journal of dermatology.

[5]  S. Ibbotson,et al.  A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma , 2008, The Journal of dermatological treatment.

[6]  S. Rosso,et al.  FULL PAPER , 2020, VALUE.

[7]  C. Ferrándiz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle‐controlled phase III study in Europe , 2005, The British journal of dermatology.

[8]  L. Golitz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.

[9]  H. Williams,et al.  Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. , 2014, The Lancet. Oncology.